Valeant stock has lost a quarter of its value since reporting its ... The company …
An analyst apologized to clients late Wednesday for his calls on troubled biotechnology company Dendreon Corp., as he moved his rating on the shares to hold from buy in the wake of the company lowering sales estimates for the coming …
I talked to Greg Schiffman, Dendreon’s CFO, this morning on the company’s announcement that it would raise about $46 million, after fees, by selling some of its stock to an institutional investor. Below are some highlights of that interview.
Shares of Dendreon (Nasdaq: DNDN) are trading significantly higher ... But how much room is left to run in the stock? …
Heavy call buying accompanied the stock move triggered by takeover speculation,” said Frederic Ruffy, option strategist at Web information site WhatsTrading.com. Dendreon has said it is not interested in being acquired, and that it intends …
Many investors appear to be quite bearish on Dendreon Corporation (DNDN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 26.92% of the float is sold short, suggesting an extreme level of …
an investor, purporting to represent a class consisting of persons who purchased Dendreon common stock between April 29, 2010 and August 3, 2011, sought unspecified damages from Dendreon and three current and former officers of the …
and whose disease has spread to the lungs or the brain. Previously, patients whose cancer spread to the brain or lungs were not covered. Patients whose disease has spread to the liver still are not covered. Dendreon's shares closed 3.9 …
The plaintiff alleges that certain defendants knew the rosy statements were "completely false" and unlike defendants, …
The Notes will be convertible into cash, shares of Dendreon's common stock (the "Common Stock") or a combination of cash and shares of Common Stock, at Dendreon's election. Dendreon also granted the underwriter of the offering of …